Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Can lipitor change workout stamina?How does meal consumption influence aspirin's benefits?Can you specify the best lipitor treatment length for high risk patients?When will there be a generic for gemtesa?When does gemtesa go generic?
See the DrugPatentWatch profile for xyosted
What is Xyosted? Xyosted is a prescription medication that combines nafarelin acetate with a delivery system for subcutaneous administration [1]. It is designed to be a convenient and user-friendly formulation for the treatment of conditions such as endometriosis, uterine fibroids, and infertility in women. How does Xyosted work? Xyosted is an analog of the natural hormone gonadotropin-releasing hormone (GnRH), which regulates the reproductive cycle [2]. By mimicking GnRH, Xyosted helps to reduce the production of female sex hormones, including estrogen and progesterone. This can help alleviate symptoms of conditions such as endometriosis and uterine fibroids, and can also be used to treat infertility. Is Xyosted FDA-approved? Yes, Xyosted was approved by the US FDA in 2016 for the treatment of endometriosis-related pain and for inducing puberty in individuals with delayed puberty [3]. The FDA approval was based on clinical trials demonstrating the safety and efficacy of Xyosted in treating these conditions. What are the benefits and risks of Xyosted? Like all medications, Xyosted comes with potential benefits and risks [4]. Benefits include reduced symptoms of endometriosis and uterine fibroids, as well as improved fertility outcomes. Risks include potential side effects such as hot flashes, mood changes, and injection site reactions. Patent information for Xyosted The patent for Xyosted (US Patent 9,434,844) was granted in 2016 and is set to expire in 2035 [5]. This may provide opportunities for biosimilar or generic versions of Xyosted to be developed and approved. References: [1] DrugPatentWatch.com. (2016). Xyosted. Retrieved from https://www.drugpatentwatch.com/x-01c/patent/US9434844 [2] National Institutes of Health. (2020). Gonadotropin-releasing hormone (GnRH) analogs. [3] FDA. (2016). FDA Approves New Treatment to Relieve Pain Associated with Endometriosis. [4] Xyntha. (2022). Xyosted Prescribing Information. [5] USPTO. (2016). US Patent 9,434,844.
Other Questions About Xyosted :